Advertisement

Topics

Multiple Myeloma Research Foundation and Adaptive Biotechnologies Company Profile

07:10 EST 11th December 2018 | BioPortfolio

Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-Cell and B-Cell Receptors. This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis and monitoring of cancer patients. For more information, please visit AdaptiveBiotech.com.


News Articles [1913 Associated News Articles listed on BioPortfolio]

Sanofi to use Adaptive’s NGS-based assay in isatuximab multiple myeloma trials

Sanofi has agreed to use Adaptive Biotechnologies’ next generation sequencing (NGS) based assay in its active and future multiple myeloma (MM) trials with isatuximab.

Study Shows that Measuring MRD Negativity Using Adaptive’s Next-Generation Sequencing Platform is a Major Predictive Indicator in Multiple Myeloma

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies today announced that Blood, the Journal of the American Society of Hematology (ASH), published online an analysis of patient samples from ...

Adaptive and Sanofi Collaborate to Use Adaptive’s clonoSEQ Assay in Active and Future Isatuximab Multiple Myeloma Trials

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, the leader in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immu...

FDA Authorizes Adaptive’s clonoSEQ Assay to Detect MRD in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies® announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo designation for the clonoSEQ® Assay to detect and...

FDA approves first NGS test to detect minimal residual disease in two blood cancers

In a first, the agency approved Adaptive Biotechnologies’ clonoSEQ assay to detect MRD in acute lymphoblastic

Multiple Myeloma Research Foundation (MMRF) Receives Highest Rating from Charity Navigator for Exceptional Fiscal Management

MMRF Honored for Fifteenth Year for Outstanding Stewardship of Donors’ Funds The Multiple Myeloma Research Foundation (MMRF) received a 4-star rating from Charity Nav...

The MMRF CoMMpass Study Drives New Discoveries in Multiple Myeloma

NORWALK, Conn., Dec. 1, 2018 /PRNewswire/ -- Today, the Multiple Myeloma Research Foundation (MMRF) announced new discoveries driven by its landmark CoMMpass StudySM into defining Read more...

Adaptive Biotechnologies gets FDA approval for clonoSEQ assay

The clonoSEQ assay, which uses DNA from a patient’s bone marrow sample, deploys next-generation sequencing (NGS) technology to evaluate disease burden. The clonoSEQ is the first and only The post A...

PubMed Articles [3217 Associated PubMed Articles listed on BioPortfolio]

Identification specific miRNA in t(4;14) multiple myeloma based on miRNA-mRNA expressing profile correlation analysis.

Multiple myeloma (MM) is a common malignancy belonging to the hematological system. The translocation t(4;14)(p16.3;q32.3) is a critical cytogenetic change of MM, which is presenting a poor prognosis....

Organochlorine Levels in Plasma and Risk of Multiple Myeloma: Organochlorines and risk of multiple myeloma.

To estimate the association between organochlorine pesticides and polychlorinated biphenyls (PCBs) and multiple myeloma (MM).

Severe Cytomegalovirus Enterocolitis Developing following Daratumumab Exposure in Three Patients with Multiple Myeloma.

Survival of multiple myeloma (MM) patients has improved with introduction of novel anti-myeloma agents. Myeloma has transformed into a chronic condition, accompanied with multiple relapses requiring s...

Methods for determining key components in a mathematical model for tumor-immune dynamics in multiple myeloma.

In this work, we analyze a mathematical model we introduced previously for the dynamics of multiple myeloma and the immune system. We focus on four main aspects: 1) obtaining and justifying ranges and...

Multiple Myeloma - Current Standards in Surgical Treatment.

Multiple myeloma is a haematological blood cancer in elderly patients, in which neoplastic cell populations cause osteolytic destruction in the bone skeleton. More than 50% of all patients sustain pat...

Clinical Trials [5802 Associated Clinical Trials listed on BioPortfolio]

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

The purpose of this research study is to determine the safety of CCI-779 and bortezomib, and the highest dose of this drug that can be given to people safely. We will also be looking at h...

Inflammatory Cytokines in Symptom Production in Multiple Myeloma

The goal of this research study is to learn about the pain and/or other symptoms that patients may experience during and after treatment for multiple myeloma (MM) and how these symptoms ma...

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma

This research study is a Phase I/II clinical trial. It is done to determine the best doses that the investigational drug (P276-00) can be used safely. "Investigational" means that the dru...

Multiple Myeloma Molecular Monitoring Study

The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment....

Companies [3438 Associated Companies listed on BioPortfolio]

Multiple Myeloma Research Foundation and Adaptive Biotechnologies

Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-Cell and B-Cell Receptors. This breakthrough enables in-depth c...

Multiple Myeloma Research Foundation (MMRF)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, mo...

The Multiple Myeloma Research Foundation

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2009, ap...

The Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's dia...

GNS Healthcare and The Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathyâ€...

More Information about "Multiple Myeloma Research Foundation and Adaptive Biotechnologies" on BioPortfolio

We have published hundreds of Multiple Myeloma Research Foundation and Adaptive Biotechnologies news stories on BioPortfolio along with dozens of Multiple Myeloma Research Foundation and Adaptive Biotechnologies Clinical Trials and PubMed Articles about Multiple Myeloma Research Foundation and Adaptive Biotechnologies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Multiple Myeloma Research Foundation and Adaptive Biotechnologies Companies in our database. You can also find out about relevant Multiple Myeloma Research Foundation and Adaptive Biotechnologies Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record